Guide · Updated April 2026

Amycretin vs Tirzepatide: The Next-Gen Triple Agonist

Amycretin is Novo Nordisk's investigational GLP-1/amylin co-agonist that produced 22% weight loss in just 36 weeks in phase 2 trials, a faster trajectory than tirzepatide's 22.5% over 72 weeks in SURMOUNT-1 (NEJM, 2022). Tirzepatide (sold as Mounjaro and Zepbound) is FDA-approved and available now at $349-$499/month through LillyDirect. Amycretin is entering phase 3 trials with no approval expected before 2028.

Novo Nordisk needs a winner. Tirzepatide outsells their own semaglutide (Wegovy, Ozempic) on pure weight loss numbers, and the head-to-head SURMOUNT-5 trial (NEJM, May 2025) confirmed it: tirzepatide produced 20.2% weight loss versus semaglutide’s 13.7% at max doses. So Novo Nordisk built something different. Amycretin does not just tweak the GLP-1 receptor. It combines GLP-1 activity with amylin receptor activation in a single molecule, targeting appetite through a pathway that tirzepatide does not touch.

The question for anyone following the amycretin vs tirzepatide comparison: does a new mechanism actually translate into better results, or is this just a corporate arms race?

How These Drugs Work (Different Mechanisms)

Understanding the mechanism matters here because these two drugs take genuinely different approaches to weight loss.

Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. GLP-1 slows gastric emptying and reduces appetite. GIP appears to enhance fat metabolism and may improve how the body handles insulin. The combination produced the best weight loss numbers of any approved drug in the SURMOUNT-1 trial (NEJM, July 2022): 22.5% at the 15mg dose over 72 weeks.

Amycretin takes a different path. Instead of pairing GLP-1 with GIP, Novo Nordisk paired GLP-1 with amylin receptor activation. Amylin is a hormone your pancreas releases alongside insulin after meals. It signals to the brainstem that you are full, slows stomach emptying, and suppresses glucagon (which raises blood sugar). By combining GLP-1 and amylin signaling in one molecule, amycretin hits appetite control from two distinct brain pathways.

The distinction matters because GIP (tirzepatide’s second target) and amylin (amycretin’s second target) do fundamentally different things. GIP works more on metabolic efficiency. Amylin works more on satiety signaling in the brain. Early data suggests amycretin’s approach may produce faster weight loss, though we need phase 3 data to confirm.

For context on how the current generation of GLP-1 medications actually works for weight loss, that guide covers the basics.

Amycretin vs Tirzepatide: Weight Loss Data

Here is where things get interesting, and where you need to be careful about comparing numbers across different trials.

Tirzepatide (SURMOUNT-1)

The gold standard data comes from SURMOUNT-1 (NEJM, July 2022), which enrolled 2,539 adults with obesity and no diabetes over 72 weeks:

At the 15mg dose, 91% of participants lost at least 5% of their body weight, and 57% lost 20% or more. Those are remarkable numbers. The SURMOUNT-5 head-to-head trial later confirmed tirzepatide outperforms semaglutide by a wide margin: 20.2% vs 13.7% weight loss, with 47% more total weight lost.

Amycretin (Phase 2)

Amycretin’s phase 2 data showed 22% weight loss at 36 weeks. Read that again. The same percentage of weight loss that tirzepatide achieved in 72 weeks, amycretin reached in half the time.

Now the caveats. Phase 2 trials are smaller, shorter, and the patient populations may differ. We do not know whether amycretin’s weight loss curve continues climbing past 36 weeks or plateaus. We also do not know how the side effect profile looks at scale. Every obesity drug looks better in phase 2 than it does once tens of thousands of real patients start using it.

But the trajectory is hard to ignore.

Head-to-Head Comparison

I have been on Mounjaro for over six months now, and my own results tracked close to the trial data. The idea that something could work even faster is genuinely compelling, but I have learned to wait for large-scale data before getting excited about phase 2 results.

The Pipeline Context

Amycretin is not the only next-gen obesity drug in development. It sits in a crowded pipeline, and understanding where it fits helps frame the amycretin vs tirzepatide comparison.

Retatrutide is the true triple agonist in this list, targeting GLP-1, GIP, and glucagon receptors simultaneously. Its phase 2 results (28.7% weight loss at the highest dose) are the best anyone has seen. But it is still in phase 3.

CagriSema is worth noting because it is also from Novo Nordisk and also targets amylin, but as a combination of two separate drugs (semaglutide plus cagrilintide) rather than a single molecule. Amycretin’s advantage is that it combines both activities in one compound, which could mean simpler dosing and manufacturing.

For anyone looking at what is available right now, see our breakdown of oral vs injectable GLP-1 options or check the provider directory for current pricing on tirzepatide and semaglutide.

Side Effects: What We Know So Far

Tirzepatide’s side effect profile is well documented from large phase 3 trials. Amycretin’s is not.

Tirzepatide (SURMOUNT-1 Data)

One thing that stood out in the SURMOUNT-5 head-to-head: tirzepatide actually had fewer GI-related dropouts than semaglutide (2.7% vs 5.6%). For practical tips on handling these, see our guide on managing nausea on Mounjaro.

Amycretin (Phase 2 Data)

Novo Nordisk has reported that GI side effects with amycretin were “consistent with the GLP-1 class,” meaning nausea, vomiting, and diarrhea were common. But specific rates from the phase 2 trial have not been fully published as of April 2026.

The amylin component adds a theoretical concern. Amylin-based drugs like pramlintide (Symlin, approved for diabetes) are known to cause nausea, especially early in treatment. Whether combining amylin activation with GLP-1 in a single molecule changes the side effect dynamic is something phase 3 trials will need to answer.

If you are currently managing GLP-1 side effects, the strategies that work for tirzepatide and semaglutide (slow titration, smaller meals, staying hydrated) would likely apply to amycretin as well.

Body Composition: The Real Question

Weight loss percentages grab headlines, but what matters more is what kind of weight you lose. Losing muscle along with fat is the central concern with every obesity drug, and it is something I track closely with DEXA scans.

What We Know About Tirzepatide

SURMOUNT-1 showed that about 34% of total weight lost on tirzepatide was lean mass. Fat mass decreased by 33.9% while lean mass decreased by 10.9%. The overall lean-to-fat ratio actually improved, meaning you end up with a better body composition even though you lose some muscle.

That 34% lean mass loss figure is better than semaglutide’s (39-45% of total weight lost was lean mass in STEP 1), but it is still a real concern. I have written extensively about muscle preservation strategies on GLP-1s and why resistance training is non-negotiable.

What We Know About Amycretin

Almost nothing, yet. Phase 2 trials rarely include detailed body composition data from DEXA scans. We do not know whether amycretin’s faster weight loss comes at the expense of more muscle loss or whether the amylin pathway somehow preserves lean mass better.

This is one of the biggest unanswered questions. If amycretin produces 22% weight loss in 36 weeks but the lean-to-fat ratio is worse than tirzepatide, that changes the calculus significantly. Until phase 3 body composition data is published, anyone comparing these two drugs is missing a critical piece of the puzzle.

For anyone on a GLP-1 right now, the body composition guide and exercise protocol cover what actually helps preserve muscle during rapid weight loss.

Cost and Availability

This is where the comparison gets simple, because only one of these drugs exists as a product you can buy.

Tirzepatide: Available Now

If cost is the primary concern, our guide to the cheapest GLP-1 options online breaks down every pathway.

Amycretin: Not Available

Amycretin is entering phase 3 clinical trials. It is not available for purchase anywhere. The most optimistic timeline puts FDA approval in late 2028 or 2029, assuming phase 3 results are positive and the regulatory process moves smoothly.

You cannot buy amycretin from a compounding pharmacy either. Unlike semaglutide and tirzepatide, amycretin has no FDA shortage designation and no approved version to compound from.

Who Should Care About Amycretin?

If you are starting GLP-1 treatment now: Tirzepatide is the stronger choice based on available data. It is FDA-approved, widely available, and has the best weight loss results of any approved obesity medication. Waiting for amycretin means waiting at least two to three years with no guarantee it will outperform what already exists.

If you are on semaglutide and plateauing: Consider switching to tirzepatide rather than waiting for amycretin. The SURMOUNT-5 data showed tirzepatide produces 47% more weight loss than semaglutide at max doses.

If you are in the industry or following the science: Amycretin is worth watching. The 22% at 36 weeks trajectory, if it holds in larger trials, would represent a meaningful advance. The GLP-1/amylin mechanism is different enough from GLP-1/GIP (tirzepatide) that it could offer advantages for specific patient populations.

Bottom Line

Amycretin’s early data is promising, but tirzepatide is the better choice for anyone seeking treatment today. Tirzepatide has four years of real-world evidence, FDA approval, and the strongest weight loss data of any available medication (22.5% in SURMOUNT-1, confirmed in the SURMOUNT-5 head-to-head). Amycretin’s faster trajectory in phase 2 is noteworthy, but phase 2 results do not always survive larger trials. If you are ready to start, compare current GLP-1 providers and talk to a prescriber about tirzepatide.

FAQ

Is amycretin better than tirzepatide for weight loss?

It is too early to say. Amycretin showed 22% weight loss at 36 weeks in phase 2, a faster pace than tirzepatide’s 22.5% at 72 weeks in SURMOUNT-1. But phase 2 trials are small and short. We need phase 3 data before making direct efficacy comparisons.

When will amycretin be available?

The earliest realistic timeline is late 2028 or 2029. Amycretin is entering phase 3 clinical trials as of early 2026. Phase 3 trials typically take 2-3 years, followed by FDA review. There is no guaranteed approval date.

Is amycretin the same as CagriSema?

No. Both are from Novo Nordisk and both target amylin receptors, but they are different products. CagriSema is a combination injection of two separate drugs (semaglutide plus cagrilintide). Amycretin is a single molecule that activates both GLP-1 and amylin receptors. Amycretin is earlier in development.

Can I get amycretin from a compounding pharmacy?

No. Amycretin is an investigational drug with no FDA approval. Compounding pharmacies cannot legally produce it. It is only available through clinical trials.

What is a GLP-1/amylin co-agonist?

It is a single molecule designed to activate both the GLP-1 receptor and the amylin receptor simultaneously. GLP-1 reduces appetite and slows digestion. Amylin signals fullness to the brainstem and suppresses glucagon. Combining both in one drug targets weight loss through two distinct pathways.

Related

Guides:

• Cheapest GLP-1 Online · Insurance Coverage · Side Effects
• Mounjaro Dosage Guide · Oral vs Injectable · Exercise and Muscle
• Fat Loss vs Weight Loss · DEXA Scan Results · Mounjaro Plateau · Medicare Coverage · Wegovy Pill vs Injection

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides